Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers

NCT01390025 is registered in ClinicalTrials.gov with Theraclone Sciences, Inc. as lead sponsor.

NCT NCT01390025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01390025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers
Lead sponsor
Theraclone Sciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2011
Completion date
March 31, 2012
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human